Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12

Journal of Neurosurgery

Volumn 99, Issue 4, 2003, Pages 746-753

  Yamanaka, Ryuya ^a   Tsuchiya, Naoto ^b   Yajima, Naoki ^b   Honma, Junpei ^b   Hasegawa, Hitoshi ^b   Tanaka, Ryuichi ^b   Ramsey, Jay ^b   Blaese, Michael ^b   Xanthopoulos, Kleanthis G ^b  

^a NIIGATA UNIVERSITY   (Japan)

^b NONE

Author keywords

Dendritic cell; Immunogene therapy; Interleukin 12; Interleukin 18; Malignant brain tumor; Mouse; Semliki Forest virus

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CANCER; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; GENETIC ENGINEERING; IMMUNOGENETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEMLIKI FOREST ALPHAVIRUS; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 0141720611     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2003.99.4.0746     Document Type: Article

References (53)

1. Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86-89, 1998
2. Brunda MJ, Luistro L, Hendrzak JA, et al: Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphasis Tumor Immunol 17:71-77, 1995
3. Brunda MJ, Luistro L, Warrier RR, et al: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223-1230, 1993
4. Brunda MJ, Sulich V, Bellantoni D: The anti-tumor effect of recombinant interferon alpha or gamma is influenced by tumor location. Int J Cancer 40:807-810, 1987
5. Coughlin CM, Salhany KE, Wysocka M, et al: Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 101:1441-1452, 1998
6. Croft M, Carter L, Swain SL, et al: Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 180:1715-1728, 1994
7. Cui J, Shin T, Kawano T, et al: Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623-1626, 1997
8. Engelhardt JF, Yang Y, Stratford-Perricaudet LD, et al: Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nat Genet 4:27-34, 1993
9. Fakhrai H, Dorigo O, Shawler DL, et al: Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 93:2909-2914, 1996
10. Germann T, Rude E: Interleukin-12. Int Arch Allergy Immunol 108:103-112, 1995
11. Giovarelli MF, Cofano A, Vecchi M, et al: Interferon-activated tumor inhibition in vivo: small amounts of interferon-gamma inhibit tumor growth by eliciting host systemic immunoreactivity. Int J Cancer 37:141-148, 1986
12. Greenberg PD: Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281-355, 1991
13. Hara I, Nagai H, Miyake H, et al: Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration. Cancer Gene Ther 7:83-90, 2000
14. Hsieh CS, Macatonia SE, Tripp CS, et al: Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547-549, 1993
15. Kobayashi M, Fitz L, Ryan M, et al: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170:827-845, 1989
16. Kohno K, Kataoka J, Ohtsuki T, et al: IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol 158:1541-1550, 1997
17. Kohyama M, Saijyo K, Hayasida M, et al: Direct activation of human CD8+ cytotoxic T lymphocytes by interleukin-18. Jpn J Cancer Res 89:1041-1046, 1998
18. Levis R, Schlesinger S, Huang HV: Promoter for Sindbis virus RNA-dependent subgenomic RNA transcription. J Virol 64:1726-1733, 1990
19. Lewis J, Wesselingh SL, Griffin DE, et al: Alphavirus-induced apoptosis in mouse brains correlates with neurovirulence. J Virol 70:1828-1835, 1996
20. Manetti R, Parronchi P, Giudizi MG, et al: Natural killer cell stimulatory factor (interleukin 12 (IL-12)) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177:1199-1204, 1993
21. Martinotti A, Stoppacciaro A, Vagliani M, et al: CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol 25:137-146, 1995
22. Marzo AL, Kinnear BF, Lake RA, et al: Tumor-specific CD4(+) T cells have a major "post-licensing" role in CTL mediated antitumor immunity. J Immunol 165:6047-6055, 2000
23. Micallef MJ, Ohtsuki T, Kohno K, et al: Interferon-γ-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol 26:1647-1651, 1996
24. Micallef MJ, Yoshida K, Kawai S, et al: In vivo antitumor effects of murine interferon-γ-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 43:361-367, 1997
25. Mule JJ, Asher A, McIntosh J, et al: Antitumor effect of recombinant tumor necrosis factor-α against murine sarcomas at visceral sites: tumor size influences the response to therapy. Cancer Immunol Immunother 26:202-208, 1988
26. Mulligan RC: The basic science of gene therapy. Science 260:926-932, 1993
27. Nakamura K, Okamura H, Wada M, et al: Endotoxin-induced serum factor that stimulates interferon production. Infect Immun 57:590-595, 1989
28. Nakamura S, Otani T, Ijiri Y, et al: IFN-γ-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12. J Immunol 164:3330-3336, 2000
29. Nastala CL, Edington HD, McKinney TG, et al: Recombinant IL-12 administration induces tumor regression in association with EFN-γ production. J Immunol 153:1697-1706, 1994
30. Okamura H, Tsutsi H, Komatsu T, et al: Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378:88-91, 1995
31. Osaki T, Peron JM, Cai Q, et al: IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J Immunol 160:1742-1749, 1998
32. Ossendorp F, Mengede E, Camps M, et al: Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class H negative tumors. J Exp Med 187:693-702, 1998
33. Pardoll DM: Therapeutic vaccination for cancer. Clin Immunol 95:S44-S62, 2000
34. Piper RC, Slot JW, Li G, et al: Recombinant Sindbis virus as an expression system for cell biology. Methods Cell Biol 43:55-78, 1994
35. Rakhmilevich AL, Turner J, Ford MJ, et al: Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 93:6291-6296, 1996
36. Rosenberg SA, Mule JJ, Spiess PJ, et al: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 161:1169-1188, 1985
37. Rosenfeld MA, Siegfried W, Yoshimura K, et al: Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 252:431-434, 1991
38. Sampson JH, Ashley DM, Archer GE, et al: Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery 41:1365-1373, 1997
39. Strauss JH, Strauss EG: The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 58:491-562, 1994
40. Tahara H, Zeh HJ III, Storkus WJ, et al: Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54:182-189, 1994
41. Tahara H, Zitvogel L, Storkus WJ, et al: Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 154:6466-6474, 1995
42. Tan J, Crucian BE, Chang AE, et al: Interferon-gamma-inducing factor elicits antitumor immunity in association with interferon-gamma production. J Immunother 21:48-55, 1998
43. Toes RE, Ossendorp F, Offringa R, et al: CD4 T cells and their role in antitumor immune responses. J Exp Med 189:753-756, 1999
44. Tsung K, Meko JB, Peplinski GR, et al: IL-12 induces T helper 1-directed antitumor response. J Immunol 158:3359-3365, 1997
45. Walker W, Aste-Amezaga M, Kastelein RA, et al: IL-18 and CD28 use distinct molecular mechanisms to enhance NK cell production of IL-12-induced IFN-gamma. J Immunol 162:5894-5901, 1999
46. Xiang J, Chen Z, Huang H, et al: Regression of engineered myeloma cells secreting interferon-gamma-inducing factor is mediated by both CD4(+)/CD8(+) T and natural killer cells. Leuk Res 25:909-915, 2001
47. Yamanaka R, Tanaka R, Yoshida S, et al: Suppression of TGF-β1 in human gliomas by retroviral gene transfection enhances susceptibility to LAK cells. J Neurooncol 43:27-34, 1999
48. Yamanaka R, Yajima N, Tsuchiya N, et al: Administration of interleukin-12 and -18 enhancing the antitumoral immunity of genetically modified dendritic cells that had been pulsed with Semliki Forest virus-mediated tumor complementary DNA. J Neurosurg 97:1184-1190, 2002
49. Yamanaka R, Zullo SA, Ramsey J, et al: Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. Cancer Gene Ther 8:796-802, 2001
50. Yamanaka R, Zullo SA, Ramsey J, et al: Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J Neurosurg 97:611-618, 2002
51. Yamanaka R, Zullo SA, Tanaka R, et al: Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg 94:474-481, 2001
52. Yamanaka R, Zullo SA, Tanaka R, et al: Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12. Neurosurg Focus 9 (6):Article 7, 2000
53. Ying H, Zaks TZ, Wang RF, et al: Cancer therapy using a self-replicating RNA vaccine. Nat Med 5:823-827, 1999